Stockreport

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression [Yahoo! Finance]

ATAI Life Sciences N.V. - Common Shares  (ATAI) 
US:NASDAQ Investor Relations: ir.atai.net.cn
PDF - 55% of patients achieved a clinical response on the day after dosing and this rate of response was maintained at week 4 and week 12 - BPL-003 showed a good safety p [Read more]